TiGenix and Cellerix form cell-stem merger

TiGenix NV and Cellerix SA have announces that the two companies are to merge. The combination of TiGenix’ marketed product portfolio and pre-clinical stem cell platform with a clinical stage allogeneic stem cell platform and pipeline is part of TiGenix’ external growth strategy and is designed to position the company as an international leading player in the field of regenerative medicine and cell therapy. TiGenix has also announced its intention to raise €15 million through a public rights offering. Together with a €18 million capital increase by Cellerix investors prior to the transaction, the combined group is expected to have a proforma cash position of around €33 million at closing.

About these ads